Search Results

There are 4550 results for: content related to: Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

  1. You have free access to this content
    Omalizumab for asthma in adults and children

    Intervention Review

    The Cochrane Library

    Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters and Parameswaran Nair

    Published Online : 13 JAN 2014, DOI: 10.1002/14651858.CD003559.pub4

  2. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

    Clinical & Experimental Allergy

    Volume 35, Issue 4, April 2005, Pages: 408–416, S. T. Holgate, R. Djukanović, T. Casale and J. Bousquet

    Article first published online : 11 APR 2005, DOI: 10.1111/j.1365-2222.2005.02191.x

  3. You have free access to this content
    EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

    Allergy

    Volume 70, Issue 7, July 2015, Pages: 727–754, O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, O. Palomares, C. Schmidt-Weber, H.-U. Simon, U. C. Steiner, A. Vultaggio, C. A. Akdis and F. Spertini

    Article first published online : 24 APR 2015, DOI: 10.1111/all.12616

  4. You have free access to this content
    An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma

    Allergy

    Volume 63, Issue 6, June 2008, Pages: 670–684, S. D. Sullivan and F. Turk

    Article first published online : 25 APR 2008, DOI: 10.1111/j.1398-9995.2008.01723.x

  5. Safety and tolerability of omalizumab

    Clinical & Experimental Allergy

    Volume 39, Issue 6, June 2009, Pages: 788–797, J. Corren, T. B. Casale, B. Lanier, R. Buhl, S. Holgate and P. Jimenez

    Article first published online : 17 MAR 2009, DOI: 10.1111/j.1365-2222.2009.03214.x

  6. You have free access to this content
    The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

    Allergy

    Volume 65, Issue 9, September 2010, Pages: 1141–1148, J. D. Campbell, D. E. Spackman and S. D. Sullivan

    Article first published online : 10 FEB 2010, DOI: 10.1111/j.1398-9995.2010.02336.x

  7. You have free access to this content
    ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review

    Allergy

    Volume 71, Issue 5, May 2016, Pages: 593–610, I. Abraham, A. Alhossan, C. S. Lee, H. Kutbi and K. MacDonald

    Article first published online : 25 FEB 2016, DOI: 10.1111/all.12815

  8. You have free access to this content
    Role of immunmodulators in allergen-specific immunotherapy

    Allergy

    Volume 66, Issue 6, June 2011, Pages: 792–797, M. V. Kopp

    Article first published online : 18 FEB 2011, DOI: 10.1111/j.1398-9995.2011.02553.x

  9. Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment

    British Journal of Dermatology

    Volume 173, Issue 2, August 2015, Pages: 404–415, M.C. Urgert, M.T. van den Elzen, A.C. Knulst, Z. Fedorowicz and E.J. van Zuuren

    Article first published online : 22 JUL 2015, DOI: 10.1111/bjd.13845

  10. You have free access to this content
    Management and treatment of chronic urticaria (CU)

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue S3, June 2015, Pages: 16–32, M. Maurer, M.K. Church, M. Gonçalo, G. Sussman and M. Sánchez-Borges

    Article first published online : 4 JUN 2015, DOI: 10.1111/jdv.13198

  11. You have free access to this content
    Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR

    Allergy

    Volume 59, Issue 7, July 2004, Pages: 709–717, A. M. Vignola, M. Humbert, J. Bousquet, L-P. Boulet, S. Hedgecock, M. Blogg, H. Fox and K. Surrey

    Article first published online : 4 JUN 2004, DOI: 10.1111/j.1398-9995.2004.00550.x

  12. Omalizumab may not inhibit mast cell and basophil activation in vitro

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 9, September 2015, Pages: 1832–1836, J. Gericke, T. Ohanyan, M.K. Church, M. Maurer and M. Metz

    Article first published online : 26 SEP 2014, DOI: 10.1111/jdv.12693

  13. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis

    Clinical & Experimental Allergy

    Volume 38, Issue 2, February 2008, Pages: 329–337, T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi and T. Ishikawa

    Article first published online : 7 DEC 2007, DOI: 10.1111/j.1365-2222.2007.02894.x

  14. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy

    Pediatric Allergy and Immunology

    Volume 24, Issue 5, August 2013, Pages: 427–433, Matthias Volkmar Kopp, Eckard Hamelmann, Meike Bendiks, Stefan Zielen, Wolfgang Kamin, Karl-Christian Bergmann, Christian Klein, Ulrich Wahn and for The DUAL study group

    Article first published online : 25 JUN 2013, DOI: 10.1111/pai.12098

  15. You have full text access to this OnlineOpen article
    Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects

    Clinical & Experimental Allergy

    Volume 44, Issue 11, November 2014, Pages: 1371–1385, J. P. Arm, I. Bottoli, A. Skerjanec, D. Floch, A. Groenewegen, S. Maahs, C. E. Owen, I. Jones and P. J. Lowe

    Article first published online : 21 OCT 2014, DOI: 10.1111/cea.12400

  16. You have free access to this content
    Relationship between pretreatment specific IgE and the response to omalizumab therapy

    Allergy

    Volume 64, Issue 12, December 2009, Pages: 1780–1787, U. Wahn, C. Martin, P. Freeman, M. Blogg and P. Jimenez

    Article first published online : 21 JUL 2009, DOI: 10.1111/j.1398-9995.2009.02119.x

  17. You have free access to this content
    Effects of omalizumab on markers of inflammation in patients with allergic asthma

    Allergy

    Volume 64, Issue 12, December 2009, Pages: 1728–1736, S. Holgate, N. Smith, M. Massanari and P. Jimenez

    Article first published online : 15 OCT 2009, DOI: 10.1111/j.1398-9995.2009.02201.x

  18. You have free access to this content
    Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 306–320, Philip J. Lowe and Didier Renard

    Article first published online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03962.x

  19. You have free access to this content
    Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

    British Journal of Clinical Pharmacology

    Volume 68, Issue 1, July 2009, Pages: 61–76, Philip J. Lowe, Stacey Tannenbaum, Aurelie Gautier and Pablo Jimenez

    Article first published online : 26 FEB 2009, DOI: 10.1111/j.1365-2125.2009.03401.x

  20. You have free access to this content
    A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab

    British Journal of Clinical Pharmacology

    Volume 63, Issue 5, May 2007, Pages: 548–561, Naoto Hayashi, Yuko Tsukamoto, William M. Sallas and Philip J. Lowe

    Article first published online : 10 NOV 2006, DOI: 10.1111/j.1365-2125.2006.02803.x